Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis

Neurology. 1999 Oct 22;53(7):1588-9. doi: 10.1212/wnl.53.7.1588.

Abstract

We studied the effect of Bacille Calmette-Guerin (BCG) vaccine as an immunomodulator in MS. According to the guidelines for clinical trials in MS, a single crossover, MRI-monitored trial was performed in 14 patients with relapsing-remitting MS. After treatment, MRI activity was significantly reduced. No major adverse effects were reported. Adjuvant therapy with BCG vaccine was safe and merits study in MS.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • BCG Vaccine / therapeutic use*
  • Brain / pathology
  • Cross-Over Studies
  • Female
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Multiple Sclerosis / diagnosis
  • Multiple Sclerosis / drug therapy*
  • Multiple Sclerosis / physiopathology
  • Recurrence
  • Treatment Outcome

Substances

  • Adjuvants, Immunologic
  • BCG Vaccine